Pathology

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Retrieved on: 
Monday, April 8, 2024
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Wolfram syndrome, Medication, Metabolism, Patient, AMX0035, Samuel, Immunology, Doctor of Philosophy, MD, Trial of the century, Amylyx Pharmaceuticals, Division, Disorder, Pathology, Pharmaceutical industry

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.

Key Points: 
  • A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.
  • Dr. Fumihiko Urano is a physician and medical researcher specializing in Wolfram syndrome.
  • Dr. Urano is a driving force in the study of Wolfram syndrome and related disorders, including WFS1-related disorders/Wolfram-like disorders.
  • As director of the Wolfram Syndrome Clinic and the Wolfram Syndrome International Registry & Clinical Study at Washington University, Dr. Urano treats patients with Wolfram syndrome and related disorders, and leads basic science, clinical, translational, and interventional studies of Wolfram syndrome and related disorders.

PredxBio and PictorLabs Forge Strategic Partnership to Advance Cancer Research and Diagnostics with Next Generation Spatial Analytics

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Science, Partnership, Patient, Biomarker, Research, Tumor microenvironment, Artificial intelligence, Cancer, Doctor of Philosophy, Biology, Pathology, LOS, College of Engineering (KNUST), Medical imaging

PITTSBURGH and LOS ANGELES, April 9, 2024 /PRNewswire-PRWeb/ -- PredxBio, Inc., a leader in spatially intelligent biology, and PictorLabs, Inc., a leading digital pathology firm pioneering AI-powered virtual staining technology, are pleased to announce a transformative partnership aimed at revolutionizing cancer research, diagnosis, and treatment.

Key Points: 
  • PredxBio is renowned for its innovative approach to unraveling the intricate circuitries of the tumor microenvironment and leveraging Explainable AI to gain deeper insights into cancer biology.
  • "This partnership represents a significant step forward in our collective efforts to transform cancer diagnostics and treatment," added Yair Rivenson, PhD, CEO of PictorLabs.
  • The partnership between PredxBio and PictorLabs represents a powerful synergy between two innovative companies dedicated to pushing the boundaries of science and technology.
  • By leveraging their respective strengths, they aim to accelerate the development of novel diagnostic tools and therapies for cancer patients worldwide.

Navigate BioPharma Services, Inc. announces collaboration with RareCyte, Inc. to provide enhanced spatial biology capabilities using the Orion™ Platform

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Digital pathology, Pathology, Associate, Partnership, Biomarker, Tumor microenvironment, Orion, Navigation, Medical imaging

This collaboration aims to leverage the complementary expertise of both companies to provide end-to-end spatial biology services for pharmaceutical and clinical institutions worldwide.

Key Points: 
  • This collaboration aims to leverage the complementary expertise of both companies to provide end-to-end spatial biology services for pharmaceutical and clinical institutions worldwide.
  • Navigate BioPharma provides years of experience in developing high-plex imaging assays and creating highly customized biomarker solutions for immuno-oncology and oncology clinical trials.
  • The Orion platform enables Navigate BioPharma to expand the degree of customization and depth of biomarker data that can be assessed to inform clinical decisions.
  • Over the past years, Navigate BioPharma has developed and validated over 125 unique multiplex immunofluorescence (mIF) assays.

BrainCheck Showcases Latest Innovations at American Medical Group Association Annual Conference

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, AMGA, Conference, Screen, Deficit spending, Risk, Patient, Tablet, American Medical Group Association, MD, D.O, Summit Health, Amnesia, Cognition, Pathology, Dementia, FDA, Medical device

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- BrainCheck, Inc., a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, will showcase its comprehensive cognitive assessment platform, including its latest innovation, Screen™, in booth #202 at the American Medical Group Association (AMGA) Annual Conference from April 9-12 in Orlando, FL. Chelsea Dugan, Vice President of Marketing, and members of the BrainCheck team will attend the event to share BrainCheck's latest technology with medical groups and health system executives nationwide.

Key Points: 
  • Chelsea Dugan, Vice President of Marketing, and members of the BrainCheck team will attend the event to share BrainCheck's latest technology with medical groups and health system executives nationwide.
  • Expertly designed with patients in mind, BrainCheck's clinically proven platform offers a comprehensive digital solution, streamlining screening, assessment, care planning, and monitoring.
  • "BrainCheck's technology has transformed the way we assess patients' cognitive health in our practice," said Eric R. Penniman, D.O., Executive Medical Director, Summit Medical Group.
  • Early detection of cognitive impairment is key to unlocking opportunities to preserve patients' brain health," said Reza Ghomi, MD, MSE, neuropsychiatrist and Chief Medical Officer at BrainCheck.

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

Retrieved on: 
Monday, March 25, 2024
ALS, Disease, KOL, University, Anterior grey column, Therapy, DSM-IV codes, Division, Medical laboratory, Pathology, Pharmaceutical industry

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET.

Key Points: 
  • MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET.
  • The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome considerations for the upcoming topline data read-out for the Phase 1b/2a trial expected in the second quarter of 2024.
  • To access the conference call, please register using the audio conference link here .
  • A webcast replay of the event will be available on the Events page of Avenue’s website at https://avenuetx.com/ .

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

Bayer and Aignostics to collaborate on next generation precision oncology

Retrieved on: 
Thursday, March 14, 2024
Algorithm, Disease, Drug discovery, Intelligence, Partnership, Patient, Hospital, Artificial intelligence, Cancer, Executive Committee, AI, Biology, Bayer, Pathology, Machine learning, Pharmaceutical industry

BERLIN, March 14, 2024 (GLOBE NEWSWIRE) -- Bayer and Aignostics GmbH today announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

Key Points: 
  • The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, and Bayer’s deep expertise in discovering and developing novel oncology therapies.
  • Under the terms of the agreement, the companies will collaborate on multiple discovery programs and initiate at least two target identification programs.
  • Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare,” said Viktor Matyas, CEO of Aignostics GmbH.
  • Aignostics will receive an upfront payment and is eligible to receive success-based milestone payments and royalties on any commercialized therapies that result from the collaboration.

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

Retrieved on: 
Wednesday, March 13, 2024
Patient, Child, Laboratory, Duchenne muscular dystrophy, University of Oxford, School, Research, Inflammation, Electrophysiology, National Science Foundation, Immunology, Rockefeller University, Research fellow, Neuromuscular disease, Pediatrics, Pathology, SAB, IRB, CNRS, Neurology, Inflammation Research, Surgery, University, Neuro, MD, Senior, Consultant, Chemokine, Medical school, Retirement, CSO, Myopathy, Signal transduction, Doctor of Philosophy, Nursing

Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).

Key Points: 
  • Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).
  • “We welcome the members of MetrioPharm’s newly established scientific advisory board,” said Thomas Christély, CEO of MetrioPharm.
  • “We are happy to now formally establish and introduce this panel of experts for an even closer collaboration.
  • Every aspect of our research development program - from preclinical research to clinical trials - will benefit from the unparalleled expertise of our new scientific advisors.”

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, March 12, 2024
Administration, Plasma, Kidney disease, ECTS, Massachusetts General Hospital, Pyrophosphate, PD, ASN, Partnership, Pharmacokinetics, Calciphylaxis, G&A, PROPEL, Doctor of Philosophy, Chemistry, Investment, PXE, Society, Pathology, Therapy, Safety, Research and development, ESKD, ENPP1, MMSc, Natural history, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “We believe we are well-positioned to continue to advance INZ-701 through several anticipated value-creating milestones in the year ahead,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • Calciphylaxis represents a devastating condition characterized by pathologic mineralization and intimal proliferation.
  • Patients will receive 1.8 mg/kg of INZ-701 once weekly, coinciding with their hemodialysis treatment, for a total of 30 days.
  • The study’s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including PK and PD parameters.

Philips and AWS collaborate to scale digital pathology in the cloud, enhancing diagnostic capabilities and improving productivity

Retrieved on: 
Tuesday, March 12, 2024
Cloud, Diagnosis, Informatics, GM, Organization, Health, Radiology, Pathology, Education, PHG, Research, News, Cancer, AI, AWS, Workflow, HIMSS, Amazon Web Services, FMS, AEX, Medical imaging

The collaboration unites Philips’ leadership and expertise in digitization of pathology to optimize clinical workflows and AWS’ leadership in scalable, secure cloud solutions.

Key Points: 
  • The collaboration unites Philips’ leadership and expertise in digitization of pathology to optimize clinical workflows and AWS’ leadership in scalable, secure cloud solutions.
  • Philips and AWS will advance digital pathology and help pathology labs to efficiently store, manage, and analyze growing volumes of digital pathology data and enable more pathology labs to adopt digital workflows to increase productivity.
  • Philips’ collaboration with AWS has the potential to enable large scale clinical trials, multi-institute studies, and care collaboration to address complex cases, including in cancer care.
  • Philips will use AWS HealthImaging to optimize storage, increase scale and enable AI and research across the healthcare system to advance pathology image analysis and simplify clinical workflows.